Financials data is unavailable for this security.
View more
Year on year Revance Therapeutics Inc grew revenues 76.55% from 132.57m to 234.04m while net income improved from a loss of 356.42m to a smaller loss of 323.99m.
| Gross margin | 72.61% |
|---|---|
| Net profit margin | -73.20% |
| Operating margin | -67.83% |
| Return on assets | -36.38% |
|---|---|
| Return on equity | -- |
| Return on investment | -43.47% |
More ▼
Cash flow in USDView more
In 2023, Revance Therapeutics Inc increased its cash reserves by 25.85%, or 29.73m. Cash Flow from Financing totalled 136.57m or 58.35% of revenues. In addition the company used 216.58m for operations while cash from investing totalled 109.74m.
| Cash flow per share | -1.81 |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | -1.55 |
|---|---|
| Tangible book value per share | -1.63 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.12 |
|---|---|
| Quick ratio | 3.05 |
| Total debt/total equity | -- |
|---|---|
| Total debt/total capital | 1.58 |
More ▼
